Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin’s lymphoma (NHL) specifically originating from centrocyte and centroblast B cells and usually beginning in the lymph nodes. The disease is among the most common forms of NHL alongside diffuse large B-cell lymphoma (DLBCL), accounting for approximately 35% of all NHLs. 

Since its approval in 1997, most recommended regimens, particularly in the first-line setting, combine the anti-CD20 antibody Rituxan with chemotherapy. Rituximab biosimilars are now also widely available. Rituximab combined with bendamustine (BR) is a popular first-line regimen, to be followed by rituximab combined with Revlimid and R-CHOP. 

This Datamonitor Healthcare report contains a Disease Analysis module.